$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

$iova Overview Financials Valuation SEC Filings Company Website

2016 Q3 Form 10-Q Financial Statement

#000114420417055799 Filed on November 02, 2017

Income Statement

Concept	2016 Q3
Revenue	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.50M
YoY Change	291.79%
% of Gross Profit
Research & Development	$8.481M
YoY Change	70.99%
% of Gross Profit
Depreciation & Amortization	$150.0K
YoY Change	-43.61%
% of Gross Profit
Operating Expenses	$18.98M
YoY Change	148.32%
Operating Profit	-$18.98M
YoY Change	148.32%
Interest Expense	$220.0K
YoY Change	2100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$18.76M
YoY Change	145.55%
Income Tax
% Of Pretax Income
Net Earnings	-$68.21M
YoY Change	793.41%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$317.4K
COMMON SHARES
Basic Shares Outstanding	58.44M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$179.3M
YoY Change	62.85%
Cash & Equivalents	$92.90M
Short-Term Investments	$86.40M
Other Short-Term Assets	$1.300M
YoY Change	550.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$180.6M
YoY Change	63.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.769M
YoY Change	-3.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.769M
YoY Change	-3.49%
TOTAL ASSETS
Total Short-Term Assets	$180.6M
Total Long-Term Assets	$1.769M
Total Assets	$182.3M
YoY Change	62.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$228.0K
YoY Change	-80.36%
Accrued Expenses	$2.966M
YoY Change	84.45%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.194M
YoY Change	11.87%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.194M
Total Long-Term Liabilities	$0.00
Total Liabilities	$3.200M
YoY Change	10.34%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$3.000K
YoY Change	50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$179.1M
YoY Change
Total Liabilities & Shareholders Equity	$182.3M
YoY Change	62.44%

Cashflow Statement

Concept	2016 Q3
OPERATING ACTIVITIES
Net Income	-$68.21M
YoY Change	793.41%
Depreciation, Depletion And Amortization	$150.0K
YoY Change	-43.61%
Cash From Operating Activities	-$12.21M
YoY Change	217.97%
INVESTING ACTIVITIES
Capital Expenditures	-$720.0K
YoY Change	928.57%
Acquisitions
YoY Change
Other Investing Activities	-$15.63M
YoY Change	-176.54%
Cash From Investing Activities	-$16.35M
YoY Change	-180.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	500.0K
YoY Change	-70.76%
NET CHANGE
Cash From Operating Activities	-12.21M
Cash From Investing Activities	-16.35M
Cash From Financing Activities	500.0K
Net Change In Cash	-28.06M
YoY Change	-254.01%
FREE CASH FLOW
Cash From Operating Activities	-$12.21M
Capital Expenditures	-$720.0K
Free Cash Flow	-$11.49M
YoY Change	204.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q3	us-gaap	Revenues Revenues	0	USD
CY2016Q3	us-gaap	Revenues Revenues	0	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18979000	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	194000	USD
CY2016Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	221000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-22149000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-18758000	USD
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	63332	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	59113	shares
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.15
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10498000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4590000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17753000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8481000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	22343000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	18979000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-22343000	USD
	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	54029000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17200000	USD
	us-gaap	Operating Expenses OperatingExpenses	66806000	USD
	us-gaap	Operating Expenses OperatingExpenses	37717000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-66806000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-37717000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	596000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.64
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	62697	shares
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	85000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-37206000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20509000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92895000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33587000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	59308000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	96688000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	511000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-66210000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.06
	iova	Unrealized Gain Loss On Shortterm Investments UnrealizedGainLossOnShorttermInvestments	115000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	57700000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	478000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16871000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	688000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	710000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4953000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-57745000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	59705000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1086000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	58619000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	388000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2554000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55789000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	56663000	USD
	iova	Unrealized Gain Loss On Shortterm Investments UnrealizedGainLossOnShorttermInvestments	-29000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	19000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	-69000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	9208000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	15781000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2148000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-730000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1333000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2024000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1203000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	354000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	iova	Leasehold Improvements Paid By Landlord LeaseholdImprovementsPaidByLandlord	0	USD
	iova	Leasehold Improvements Paid By Landlord LeaseholdImprovementsPaidByLandlord	-155000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	54050000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	95685000	USD
CY2017Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	163400000	USD
CY2016Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	59753000	USD
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	2619000	USD
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	8645000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	9208000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	15781000	USD
CY2017Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	0	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	59753000	USD
CY2016Q4	us-gaap	Trading Securities Cost TradingSecuritiesCost	90370000	USD
CY2016Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	90399000	USD
CY2016	us-gaap	Trading Securities Unrealized Holding Gain TradingSecuritiesUnrealizedHoldingGain	61000	USD
CY2016	us-gaap	Trading Securities Unrealized Holding Loss TradingSecuritiesUnrealizedHoldingLoss	32000	USD
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2791000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2081000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5386000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4455000	USD
CY2016Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1581000	USD
CY2017Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1556000	USD
CY2017Q3	iova	Legal And Related Services Current LegalAndRelatedServicesCurrent	1236000	USD
CY2016Q4	iova	Legal And Related Services Current LegalAndRelatedServicesCurrent	927000	USD
CY2017Q3	iova	Clinical Related Expenses Current ClinicalRelatedExpensesCurrent	735000	USD
CY2016Q4	iova	Clinical Related Expenses Current ClinicalRelatedExpensesCurrent	614000	USD
CY2017Q3	iova	Manufacturing Related Expenses Current ManufacturingRelatedExpensesCurrent	1352000	USD
CY2016Q4	iova	Manufacturing Related Expenses Current ManufacturingRelatedExpensesCurrent	437000	USD
CY2017Q3	us-gaap	Accrued Rent Current AccruedRentCurrent	459000	USD
CY2016Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	422000	USD
CY2017Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	286000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	124000	USD
CY2017Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	22100000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y
CY2017Q3	us-gaap	Share Based Compensation ShareBasedCompensation	2600000	USD
CY2016Q3	us-gaap	Share Based Compensation ShareBasedCompensation	7900000	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.81
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.97
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.46
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.75
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	7084	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	6250	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	834	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	6.48
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	6.53
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	6.10
CY2016Q2	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	500000	USD
	iova	Number Of Share Options Or Share Units Exercised During Current Period NumberOfShareOptionsOrShareUnitsExercisedDuringCurrentPeriod	128500	shares
	iova	Common Stock Registered For Resale CommonStockRegisteredForResale	128500	shares
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	700000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	400000	USD
CY2017Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	300000	USD
CY2016Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
	iova	Payments For Legal Services PaymentsForLegalServices	500000	USD
	iova	Payments For Legal Services PaymentsForLegalServices	700000	USD
CY2017Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	100000	USD
CY2017Q3	iova	Payments For Legal Services PaymentsForLegalServices	100000	USD
CY2016Q3	iova	Payments For Legal Services PaymentsForLegalServices	400000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000041666
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000041666
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62248074	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71954843	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62248074	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	71954843	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22038728	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21106414	shares
CY2017Q3	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	0	USD
	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	0	USD
CY2016Q3	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	49454000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22149000	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-68212000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-66210000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-86660000	USD
	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	49454000	USD
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: 0in; MARGIN: 0in; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><u><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">NOTE 8. LEGAL PROCEEDINGS</font></u></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; TEXT-INDENT: -0.5in; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><u><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Class Action Lawsuits</font></u> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">. On April 10, 2017, the SEC announced settlements with us and with other public companies and unrelated parties in the <i>In the Matter of Certain Stock Promotion</i> investigation. Our settlement with the SEC is consistent with our previous disclosures (including in our Form 10-K that we filed with the SEC on March 9, 2017). On April 14 2017, a purported shareholder filed a class action complaint in the United States District Court, Northern District of California for violations of the federal securities laws (<i>Leonard DeSilvio v. Lion Biotechnologies, Inc., et al., case no: 3:17cv2086</i> ) against our company and three of our former officers and directors. On April 19, 2017, a second class action complaint  <i>(Amra Kuc vs. Lion Biotechnologies, Inc., et al., case no: 3:17cv2086</i>) was filed in the same court. Both complaints allege, among other things, that the defendants violated the federal securities laws by making materially false and misleading statements, or by failing to make certain disclosures, regarding the actions taken by Manish Singh, our former CEO, and our former investor relations firm that were the subject of the <i> In the Matter of Certain Stock Promotions</i> SEC investigation. On July 20, 2017 the plaintiff in the <i>Kuc</i> case filed a notice to voluntarily dismiss that case. The Court entered an order dismissing the <i>Kuc</i> complaint on July 21, 2017. On July 26, 2017, the court appointed a movant as lead plaintiff. On September 8, 2017, the lead plaintiff filed an amended complaint that alleges, among other things, that the defendants violated the federal securities laws by making materially false and misleading statements, or by failing to make certain disclosures, regarding the actions taken by Manish Singh and our former investor relations firm that were the subject of the <i>In the Matter of Certain Stock Promotions</i> SEC investigation. On October 6, 2017, the court entered an order setting a schedule for the case, which includes a briefing schedule for motions to dismiss and a hearing date of December 22, 2017.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">We intend to vigorously defend against the foregoing complaints. Based on the very early stage of the litigation, it is not possible to estimate the amount or range of possible loss that might result from an adverse judgment or a settlement of these matters.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt;FONT-FAMILY:times new roman,times,serif"><u> Solomon Capital, LLC.</u> On April 8, 2016, a lawsuit titled <i> Solomon Capital, LLC, Solomon Capital 401(K) Trust, Solomon Sharbat and Shelhav Raff v. Lion Biotechnologies, Inc.</i> was filed by Solomon Capital, LLC, Solomon Capital 401(k) Trust, Solomon Sharbat and Shelhav Raff against the Company in the Supreme Court of the State of New York, County of New York (index no. 651881/2016). The plaintiffs allege that, between June and November 2012 they provided to the Company $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.1</font> million and that they advanced and paid on our behalf an additional $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.2</font> million. The complaint further alleges that the Company agreed to (i) provide them with promissory notes totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.2</font> million, plus interest, (ii) issue a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 111,425</font> shares to the plaintiffs (before the 1-for-100 reverse split of our common stock effected in September 2013), and (iii) allow the plaintiffs to convert the foregoing funds into our securities in the next transaction. The plaintiffs allege that they should have been able to convert their advances and payments into shares of the Company’s common stock in the restructuring that was effected in May 2013. Based on the foregoing, the plaintiffs allege causes for breach of contract and unjust enrichment and demand judgment against the Company in an unspecified amount exceeding $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million, plus interest and attorneys’ fees.</font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY:times new roman,times,serif"> </font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On June 3, 2016, the Company filed an answer and counterclaims in the lawsuit. In its counterclaims, the Company alleges that the plaintiffs misrepresented their qualifications to assist it in fundraising and that they failed to disclose that they were under investigation for securities laws violations. The Company is seeking damages in an amount exceeding $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.5</font> million and an order rescinding any and all agreements that the plaintiffs contend entitled them to obtain stock in the Company.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">On April 19, 2017, the Court granted plaintiffs’ counsel’s motion to withdraw from the case. On May 25, 2017, plaintiffs filed a notice that they had hired new counsel. On June 7, 2017, the judge presiding over the case recused herself because of a conflict of interest arising from her relationship with plaintiffs’ new attorneys.  The case has been assigned to a new judge, but the court has not yet scheduled a status conference or otherwise set a schedule for the case.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company intends to vigorously defend the complaint and pursue its counterclaims.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY:times new roman,times,serif"><u>Litigation Involving Dr. Steven Fischkoff</u>.  On June 13, 2017, in an action titled <i>Steven Fischkoff v. Lion Biotechnologies, Inc. and Maria Fardis</i>, Dr. Steven Fischkoff, our former Vice President and Chief Medical Officer, filed a lawsuit against the Company in the Supreme Court of the State of New York County of New York.  Dr. Fischkoff was dismissed by the Company on March 28, 2017.  Dr. Fischkoff was terminated “for cause” as that term is defined in his employment agreement. In his complaint, Dr. Fischkoff alleges breaches of his employment agreement and violation of New York Labor Law for failure to pay monies purportedly owed to him, and seeks to recover amounts including severance pay and retention bonus (totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">300,000</font>), a prorated incentive bonus, and amounts relating to unvested options to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 150,000</font> shares of our common stock, together with prejudgment interest, costs, expenses and attorneys’ fees. On July 5, 2017, the Company filed a removal petition and removed the lawsuit to the United States District Court for the Southern District of New York, where the case has been assigned case no. 17-cv-05041.  On July 14, 2017, the Company filed a partial answer and counterclaims against Dr. Fischkoff, denying his allegations, and alleging breach of contract and related claims, breach of fiduciary duty, and state and federal trade secret misappropriation and related claims, and sought a temporary restraining order and preliminary injunction against Dr. Fischkoff.  On July 18, 2017, the court issued a temporary restraining order against Dr. Fischkoff requiring him to return Company materials, prohibiting him from disclosing or using Company materials, and granting expedited discovery, which is currently proceeding.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">We intend to vigorously defend against Dr. Fischkoff’s lawsuit and pursue the Company’s counterclaims.  Based on the very early stage of the litigation, it is not possible to estimate the amount or range of (i) a possible loss that might result from an adverse judgment or settlement of this action, or (ii) the potential recovery that might result from a favorable judgment or a settlement of this action.</div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font> </div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt;FONT-FAMILY:times new roman,times,serif"><u> Other Matters.</u> During the second quarter of 2016, warrants representing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 128,500</font> shares were exercised. The <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 128,500</font> shares of common stock had previously been registered for re-sale. However, we believe that these <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 128,500</font> warrant shares were sold by the holders in open market transactions in May 2016 at a time when the registration statement was ineffective. Accordingly, those sales were not made in accordance with Sections 5 and 10(a)(3) of the Securities Act, and the purchasers of those shares may have rescission rights (if they still own the shares) or claims for damages (if they no longer own the shares). The amount of any such liability is uncertain and as such, an accrual for any potential loss has not been made. The Company believes that any claims brought against it would not result in a material impact to the Company’s financial position or results of operations. The Company has not accrued a loss for a potential claim associated with this matter as it is unable to estimate any at this time.</font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-SIZE: 10pt;FONT-FAMILY:times new roman,times,serif">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues amounts, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss. While there can be no assurances as to the ultimate outcome of any legal proceeding or other loss contingency involving the Company, management does not believe any pending matter will be resolved in a manner that would have a material adverse effect on the Company’s financial position, results of operations or cash flows.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	iova	Offering Costs Under Accounts Payable And Accrued Expenses OfferingCostsUnderAccountsPayableAndAccruedExpenses	0	USD
	iova	Offering Costs Under Accounts Payable And Accrued Expenses OfferingCostsUnderAccountsPayableAndAccruedExpenses	235000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	3000	USD
	iova	Deemed Dividend Related To Beneficial Conversion Feature DeemedDividendRelatedToBeneficialConversionFeature	49454000	USD
	iova	Deemed Dividend Related To Beneficial Conversion Feature DeemedDividendRelatedToBeneficialConversionFeature	0	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	276000	USD
CY2017Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	6.50
CY2017Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	53800000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1023000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	700000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	495000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	169000	USD
CY2017Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2663000	USD
CY2017Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8846154	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">Use of Estimates</font></font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include valuation of short-term investments, accounting for potential liabilities, the valuation allowance associated with the Company’s deferred tax assets, and the assumptions made in valuing stock instruments issued for services.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Reclassifications</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Certain amounts within the statements of cash flows for the prior periods have been reclassified to conform with the current period presentation. These reclassifications had no impact on the Company's previously reported financial position or cash flows for any of the periods presented.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name	View Source	Status
0001144204-17-055799-index-headers.html	Edgar Link	pending
0001144204-17-055799-index.html	Edgar Link	pending
0001144204-17-055799.txt	Edgar Link	pending
0001144204-17-055799-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
iova-20170930.xml	Edgar Link	completed
iova-20170930.xsd	Edgar Link	pending
iova-20170930_cal.xml	Edgar Link	unprocessable
iova-20170930_def.xml	Edgar Link	unprocessable
iova-20170930_lab.xml	Edgar Link	unprocessable
iova-20170930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv477548_10q.htm	Edgar Link	pending
tv477548_ex10-1.htm	Edgar Link	pending
tv477548_ex31-1.htm	Edgar Link	pending
tv477548_ex31-2.htm	Edgar Link	pending
tv477548_ex32-1.htm	Edgar Link	pending
tv477548_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

2016 Q3 Form 10-Q Financial Statement

#000114420417055799 Filed on November 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IOVA IOVANCE BIOTHERAPEUTICS, INC. Stock $iova

2016 Q3 Form 10-Q Financial Statement

#000114420417055799 Filed on November 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IOVA
IOVANCE BIOTHERAPEUTICS, INC. Stock $iova